Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at #ESMO24 in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n

In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami

The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors

Director of Programs and Outreach Lisa Yen interviews Dr Michael Soulen, Interventional Radiologist at Penn. He talks about the highlights of 2023 and shares his hopes for 2024.

Director of Programs and Outreach Lisa Yen interviews NANETS Past President, Dr. Pamela Kunz. She talks about the highlights of 2023 and shares her hopes for 2024.

Director of Programs and Outreach Lisa Yen interviews Dr. Jonathan Strosberg, Medical Oncologist at Moffitt. He talks about the highlights of 2023 and shares his hopes for 2024.

Director of Programs and Outreach Lisa Yen interviews NANETS President Dr. Thor Halfdanarson. He talks about the highlights of 2023 and shares his hopes for 2024.

Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future. Click here to read the detailed results of the CABINET trial announcement (https://www.businesswire.com/news/home/20231020586023/en/Detailed-Results-from-Phase-3-CABINET-Pivotal-Trial-Evaluating-Cabozantinib-in-Advanced-Neuroendocrine-Tumors-Presented-at-ESMO-2023?fbclid=IwAR18JTeSfpDVo9upMsyTrKssQfvT5vBrr0ifXJUaEKWDKh4nEcHQtRqC_M8) or the OncLive article here (https://www.onclive.com/view/cabozantinib-confers-pfs-benefit-in-previously-treated-advanced-neuroendocrine-tumors?fbclid=IwAR2bcn_e_CHS65aS5jQGaFvxG_NrE6mU-xnHfU6C33FH0DUL_i7g6yKrc10). Watch this exclusive video interview below with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain.